Analysts on Wall Street project that Envista (NVST) will announce quarterly earnings of $0.33 per share in its forthcoming report, representing a decline of 36.5% year over year. Revenues are projected to reach $632.7 million, declining 4.3% from the same quarter last year.The current level reflects an upward revision of 0.5% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over ...

BREA, Calif., Jan. 31, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") announced today that it has joined Women in DSO® as a Platinum Industry partner. Women in DSO advances and empowers female professionals, specifically in the dental support organization (DSO) industry. Envista was invited to partner because of its demonstrated commitment to advancing female leadership in dentistry and its working relationship with many of the nation's largest DSOs. As part of the partnership, E ...

The market expects Envista (NVST) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

 BREA, Calif., Jan. 16, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced that the company will hold an Investor Event at the Envista Summit on Friday, February 16, from 8:00 a.m. to 10:45 a.m. PST. This event will include a management presentation followed by an interactive question-and-answer section. Due to space limitations, in-person attendance requires advanced registration. Those interested in attending the event in person can contact [email protected] for more informatio ...

BREA, Calif., Jan. 11, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its fourth quarter 2023 on Wednesday, February 7, 2024. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after th ...

Third Quarter 2023 2 Progress on Strategic Priorities 4 Adjusted EBITDA* $123.5M 5 Core Sales Growth* 0.8% − Western Europe delivered DD growth − Continue to invest in long-term growth initiatives • Orthodontics − Spark continues to outperform; Strong growth in Europe & North America • Implant-based Tooth Replacements 20.8% 19.7% • Profitability investments in Spark acceleration & other growth initiatives Adjusted Operating Profit Margin* Sales Adjusted Operating Margin ($ m) 26.1% 24.6% Q3 2022 Q3 2023 • P ...

PART I. FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited Condensed Consolidated Financial Statements for the period ended June 30, 2023, covering balance sheets, operations, cash flows, and notes Condensed Consolidated Balance Sheets Condensed Consolidated Balance Sheets (Unaudited, $ in millions) | | June 30, 2023 | December 31, 2022 | | :--- | :--- | :--- | | **Total current assets** | $1,488.9 | $1,424.6 | | **Total assets** | $6,607.2 | $6,587.0 | | **Total current liabilities** | $1,150.8 | $1,236.7 | | **Total liabilities** | $2,296.2 | $2,380.1 | | **Total stockholders' equity** | $4,311.0 | $4,206.9 | | **Total liabilities and stockholders' equity** | $6,607.2 | $6,587.0 | Condensed Consolidated Statements of Operations Condensed Consolidated Statements of Operations (Unaudited, $ in millions, except per share amounts) | | Three Months Ended June 30, 2023 | Three Months Ended July 1, 2022 | Six Months Ended June 30, 2023 | Six Months Ended July 1, 2022 | | :--- | :--- | :--- | :--- | :--- | | **Sales** | $662.4 | $645.8 | $1,289.6 | $1,277.2 | | **Gross profit** | $378.6 | $369.8 | $741.3 | $743.9 | | **Operating profit** | $78.9 | $65.2 | $151.0 | $156.7 | | **Net income** | $51.9 | $47.1 | $95.7 | $122.0 | | **Earnings - diluted (per share)** | $0.29 | $0.26 | $0.54 | $0.68 | Condensed Consolidated Statements of Cash Flows Condensed Consolidated Statements of Cash Flows (Unaudited, $ in millions) | | Six Months Ended June 30, 2023 | Six Months Ended July 1, 2022 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $78.2 | $25.7 | | **Net cash used in investing activities** | $(24.8) | $(586.5) | | **Net cash provided by financing activities** | $1.1 | $7.1 | | **Net change in cash and cash equivalents** | $44.8 | $(550.5) | | **Ending balance of cash and cash equivalents** | $651.7 | $523.1 | Notes to Condensed Consolidated Financial Statements This section details the company's accounting policies and financial statement line items, covering business segments, acquisitions, divestitures, revenue recognition, debt structure, and segment performance - The company operates in two segments: Specialty Products & Technologies (dental implants, orthodontics) and Equipment & Consumables (digital imaging, restorative materials)[22](index=22&type=chunk) - In 2022, the company acquired Osteogenics for **~$128.2 million** and Carestream Dental's Intraoral Scanner Business for **~$580.3 million**[33](index=33&type=chunk)[34](index=34&type=chunk) - The sale of the KaVo Treatment Unit and Instrument Business was completed as of December 31, 2022, resulting in no discontinued operations reported for the periods ended June 30, 2023[38](index=38&type=chunk)[39](index=39&type=chunk) Total Debt Components as of June 30, 2023 ($ in millions) | Debt Component | Amount | | :--- | :--- | | Senior term loan facility due 2024 | $648.8 | | Senior euro term loan facility due 2024 | $226.8 | | Convertible senior notes due 2025 | $511.5 | | **Total debt** | **$1,387.1** | Sales by Segment (Six Months Ended, $ in millions) | Segment | June 30, 2023 | July 1, 2022 | | :--- | :--- | :--- | | Specialty Products & Technologies | $827.0 | $804.8 | | Equipment & Consumables | $462.6 | $472.4 | | **Total** | **$1,289.6** | **$1,277.2** | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's financial performance for Q2 and H1 2023, focusing on sales growth, currency impacts, interest costs, segment performance, and liquidity Overview and Key Trends This section outlines the company's global dental product operations, highlighting the negative impact of foreign currency exchange rates and challenges from global economic conditions - For Q2 2023, **52.7% of sales** were derived from customers outside the United States[110](index=110&type=chunk) - Currency exchange rates negatively impacted reported sales by **1.2% for Q2 2023** and **1.4% for H1 2023** compared to the prior year periods[112](index=112&type=chunk) - The company's growth strategy includes future acquisitions, having completed two in 2022 (Osteogenics and Carestream's Intraoral Scanner Business)[118](index=118&type=chunk)[119](index=119&type=chunk)[120](index=120&type=chunk) Consolidated Results of Operations This section details consolidated financial performance, noting Q2 2023 sales growth and operating profit increase, H1 2023 sales growth, and the impact of product mix, inflation, and higher interest rates on margins and expenses Core Sales Growth Reconciliation (Non-GAAP) | | % Change Q2 2023 vs Q2 2022 | % Change H1 2023 vs H1 2022 | | :--- | :--- | :--- | | **Total sales growth (GAAP)** | **2.6%** | **1.0%** | | Impact of Acquisition | (1.7)% | (2.5)% | | Impact of Currency exchange rates | 1.2% | 1.4% | | **Core sales growth (non-GAAP)** | **2.1%** | **(0.1)%** | - Gross profit margin for H1 2023 was **57.5%**, down from **58.2% in H1 2022**, primarily due to unfavorable product mix and inflation[130](index=130&type=chunk)[131](index=131&type=chunk) - Interest expense for H1 2023 increased by **177.2% to $34.1 million**, mainly due to higher interest rates on variable-rate debt[127](index=127&type=chunk)[136](index=136&type=chunk) Results of Operations - Business Segments This section analyzes segment performance, noting sales growth in Specialty Products & Technologies with margin decline, and sales growth in Equipment & Consumables with margin improvement in Q2 2023 Specialty Products & Technologies Performance (Q2 2023 vs Q2 2022) | Metric | Q2 2023 | Q2 2022 | % Change | | :--- | :--- | :--- | :--- | | Sales | $417.0M | $407.7M | +2.3% | | Core Sales Growth | 1.7% | - | - | | Operating Profit Margin | 13.4% | 18.2% | -4.8 p.p. | Equipment & Consumables Performance (Q2 2023 vs Q2 2022) | Metric | Q2 2023 | Q2 2022 | % Change | | :--- | :--- | :--- | :--- | | Sales | $245.4M | $238.1M | +3.1% | | Core Sales Growth | 2.9% | - | - | | Operating Profit Margin | 19.7% | 12.7% | +7.0 p.p. | Liquidity and Capital Resources This section assesses the company's strong liquidity, highlighting increased operating cash flow and substantial cash and cash equivalents, deemed sufficient for future funding needs - Net cash from operating activities increased to **$78.2 million in H1 2023** from **$25.7 million in H1 2022**[157](index=157&type=chunk)[159](index=159&type=chunk) - Net cash used in investing activities was **$24.8 million in H1 2023**, compared to **$586.5 million in H1 2022**, which included significant acquisition payments[157](index=157&type=chunk)[161](index=161&type=chunk) - As of June 30, 2023, the company had **$651.7 million in cash and cash equivalents**, with **$499.3 million held outside the United States**[165](index=165&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=41&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section reports no material changes to the company's market risk disclosures from its Annual Report on Form 10-K for the year ended December 31, 2022 - There were no material changes to the company's market risk disclosures during the quarter ended June 30, 2023[174](index=174&type=chunk) [Controls and Procedures](index=41&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2023, with no material changes to internal control over financial reporting during the quarter - The President and CEO, and the SVP and CFO concluded that the company's disclosure controls and procedures were effective as of the end of the period[175](index=175&type=chunk) - No changes occurred during the quarter that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[176](index=176&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=42&type=section&id=Item%201.%20Legal%20Proceedings) This section reports no material changes to the company's legal proceedings from its 2022 Annual Report on Form 10-K - There have been no material changes to legal proceedings from the 2022 10-K[178](index=178&type=chunk) [Risk Factors](index=42&type=section&id=Item%201A.%20Risk%20Factors) This section indicates no material changes to the risk factors previously disclosed in the company's 2022 Annual Report on Form 10-K - There have been no material changes from the risk factors disclosed in the 2022 Form 10-K[179](index=179&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=42&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section reports no unregistered sales of equity securities or use of proceeds during the period - No unregistered sales of equity securities or use of proceeds were reported during the period[180](index=180&type=chunk) [Other Information](index=42&type=section&id=Item%205.%20Other%20Information) This section discloses that no directors or officers adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the quarter - During the quarter ended June 30, 2023, none of the Company's directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement"[183](index=183&type=chunk) [Exhibits](index=43&type=section&id=Item%206.%20Exhibits) This section provides an index of exhibits filed with the Form 10-Q, including corporate governance documents, a separation agreement, and CEO/CFO certifications - Exhibits filed include CEO and CFO certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act[186](index=186&type=chunk)

Envista Holdings Corporation (NYSE:NVST) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Stephen Keller - VP, IR Amir Aghdaei - President and CEO Howard Yu - CFO Conference Call Participants Elizabeth Anderson - Evercore ISI Jeff Johnson - Baird Erin Wright - Morgan Stanley Jon Block - Stifel Michael Cherny - Bank of America Brandon Vazquez - William Blair Operator My name is David, and I will be your conference call facilitator this afternoon. At this time, I would like to welc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR Securities Registered Pursuant to Section 12(b) of the Act: | Title of each class | Trading symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common stock, $0.01 par value | NVST | New York Stock Exchange | Indicate ...

Sales Performance - Specialty Products & Technologies accounted for 62% of total annual sales in 2022, up from 60% in 2021 and 58% in 2020[58]. - Emerging markets generated $563 million in sales in 2022, a significant increase from less than $30 million in 2011[51]. - The company generated 51% of its sales from markets outside of the U.S. in 2022, highlighting its global commercial reach[56]. - In 2022, 53% of sales were generated in North America, 20% in Western Europe, 22% in emerging markets, and 5% in other developed markets[73]. - Sales increased by 2.4% year-over-year, with core sales rising by 4.1% for the year ended December 31, 2022, despite a 3.5% negative impact from foreign currency exchange rates[302]. - Total sales for the year ended December 31, 2022, were $2,569.1 million, representing a 2.4% increase compared to $2,508.9 million in 2021[314]. Product Development and Innovation - The company has invested in its Specialty Products & Technology segment, adding manufacturing capacity and personnel, with further investments planned for 2023[46]. - The company has launched several new products in its Orthodontic Solutions business, contributing meaningfully to overall sales in the segment[51]. - The DTX software suite, integrating treatment planning and imaging, enhances clinical workflow efficiencies and outcomes[62]. - Spark clear aligner system, launched in multiple markets, is designed for mild to complex malocclusion and features advanced material for efficiency and aesthetics[66]. - The company launched over 30 new products since the acquisition of Nobel Biocare in 2014, including comprehensive software packages for dental treatment planning[62]. - The company is actively pursuing new product launches and commercial investments as part of its growth strategy, focusing on expanding the use of existing products and technologies[286]. Market Trends and Growth Drivers - The global dental products market is expected to grow due to an aging population, with nearly 1 billion people aged 60 or over in 2020, projected to double by 2050[55]. - The growth of Dental Service Organizations (DSOs) is expected to drive increasing penetration and access to dental care globally[55]. - The demand for dental procedures is expected to grow due to factors such as an aging population and increasing access to complex procedures[289]. - The implant industry enjoys higher margins and growth than the overall dental products market, with significant growth expected in the U.S. and Greater China[52]. Financial Performance - Operating profit for 2022 was $319.2 million, a 4.2% increase from $306.2 million in 2021, with an operating profit margin of 12.4%[314][323]. - Gross profit margin improved to 57.4% in 2022 from 56.9% in 2021, driven by increased sales volume and pricing[320][321]. - Net income for 2022 was $243.1 million, a decrease of 28.6% from $340.5 million in 2021[314]. - Operating profit margin increased to 17.8% for the year ended December 31, 2022, compared to 15.4% in 2021, driven by higher sales prices and a favorable product mix[340]. Challenges and Risks - The ongoing COVID-19 pandemic has led to a decrease in sales in certain markets, particularly in China, due to lockdowns and subsequent increases in infection rates[284]. - The company is facing challenges related to pricing transparency and reimbursement reductions from third-party payors, which could impact product demand[116]. - Regulatory scrutiny over product pricing has intensified, with various legislative efforts aimed at increasing transparency and controlling costs[115]. - Supply chain disruptions and labor shortages continue to pose challenges, impacting the ability to reliably produce and ship products[294]. - The Russia-Ukraine conflict has not materially impacted the company's financial position as of December 31, 2022, but poses risks related to market access and supply chain disruptions[285]. Human Capital and Corporate Governance - As of December 31, 2022, the company employed approximately 12,700 persons, with about 3,000 in the U.S. and 9,700 outside the U.S.[84]. - The company maintained 99% gender pay equity and 99% race/ethnicity pay equity in the U.S. in 2022[86]. - The company achieved a 91% participation rate in its employee engagement survey, with 78% of respondents feeling engaged at work[91]. - The company’s Board of Directors reviews human capital matters quarterly, focusing on talent acquisition, retention, and diversity initiatives[85]. Research and Development - Research and development investments are expected to continue at a rate consistent with past practices to maintain competitive positioning and enter new markets[80][81]. - The company has invested approximately $287.3 million in research and development (R&D) since 2020, emphasizing its commitment to product innovation and development[286]. - Research and development expenses were $100.1 million, consistent with 2021, representing 3.9% of total sales[323][324]. Cash Flow and Financing - Net cash provided by operating activities was $182.7 million in 2022, down from $361.6 million in 2021, primarily due to lower net income and higher incentive compensation payouts[345]. - Net cash used in investing activities was $657.3 million in 2022, compared to $262.7 million provided in 2021, largely due to acquisitions and increased capital expenditures[347]. - Net cash provided by financing activities was $12.5 million in 2022, a significant improvement from $465.6 million used in 2021, attributed to the repayment of a Euro Term Loan Facility[349]. - The company had the ability to incur an additional $750 million of indebtedness under its revolving credit facility as of December 31, 2022[351]. Compliance and Regulatory Matters - The company is subject to multiple data privacy and security laws, including HIPAA and GDPR, which impose significant compliance requirements and potential penalties for violations[123][119]. - Compliance with the EU Medical Device Regulation (EU MDR) required modifications to the company's quality management systems and additional resources[110]. - Compliance with state and federal data breach notification laws is critical, as violations can lead to significant legal and financial repercussions[121]. - The company is required to adhere to various export/import control laws, which may affect its operations and transactions[128].